|
gptkbp:instanceOf
|
gptkb:antibiotic
|
|
gptkbp:administeredBy
|
oral
inhalation
intravenous
|
|
gptkbp:alsoKnownAs
|
gptkb:polymyxin_E
|
|
gptkbp:ATCCode
|
J01XB01
|
|
gptkbp:availableOn
|
colistimethate sodium
colistin sulfate
|
|
gptkbp:CASNumber
|
1264-72-8
|
|
gptkbp:category
|
polymyxin antibiotic
|
|
gptkbp:chemicalFormula
|
C52H98N16O13
|
|
gptkbp:contraindication
|
gptkb:myasthenia_gravis
|
|
gptkbp:discoveredBy
|
Jean-François Doré
|
|
gptkbp:discoveredIn
|
1949
|
|
gptkbp:eliminatedIn
|
renal
|
|
gptkbp:eliminationHalfLife
|
3-5 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
colistin
|
|
gptkbp:includedIn
|
gptkb:WHO_Model_List_of_Essential_Medicines
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
1959
|
|
gptkbp:mechanismOfAction
|
disrupts bacterial cell membrane
|
|
gptkbp:meltingPoint
|
Not well defined (decomposes)
|
|
gptkbp:molecularWeight
|
1155.45 g/mol
|
|
gptkbp:notEffectiveAgainst
|
Gram-positive bacteria
anaerobes
|
|
gptkbp:notRecommendedFor
|
routine use
|
|
gptkbp:origin
|
natural product
isolated from Bacillus polymyxa var. colistinus
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:producedBy
|
gptkb:Paenibacillus_polymyxa
|
|
gptkbp:PubChem_CID
|
5311054
DB00781
|
|
gptkbp:resistantTo
|
mcr-1
|
|
gptkbp:riskFactor
|
gptkb:antibiotic
|
|
gptkbp:sideEffect
|
nephrotoxicity
neurotoxicity
|
|
gptkbp:solubility
|
water soluble
|
|
gptkbp:spectrumOfActivity
|
Gram-negative bacteria
|
|
gptkbp:UNII
|
5M8IY1W0F4
|
|
gptkbp:usedAs
|
last-resort antibiotic
|
|
gptkbp:usedFor
|
acinetobacter baumannii infections
cystic fibrosis (inhaled form)
klebsiella pneumoniae infections
pseudomonas aeruginosa infections
treatment of multidrug-resistant Gram-negative infections
|
|
gptkbp:usedIn
|
gptkb:veterinary_medicine
human medicine
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:Thayer-Martin_agar
gptkb:Acinetobacter_baumannii
|
|
gptkbp:bfsLayer
|
7
|